Edition:
Deutschland

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

160.22USD
18 Jan 2019
Change (% chg)

$3.66 (+2.34%)
Prev Close
$156.56
Open
$157.77
Day's High
$160.36
Day's Low
$156.38
Volume
865,768
Avg. Vol
643,050
52-wk High
$197.00
52-wk Low
$125.84

AGN.N

Chart for AGN.N

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Buy/Sell

Sell Hold Buy
1.95 Mean rating from 21 analysts

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35
Photo

Drug companies greet 2019 with U.S. price hikes

NEW YORK Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world's top-selling medicine, Humira, although the pace of price hikes was slower than last year.

Health Canada places restrictions on Allergan's fibroid treatment Esmya

Jan 11 Canada's health regulator on Friday said it was restricting the use of Allergan Plc's uterine fibroid treatment Esmya after discovering a risk of serious liver injury from the drug.

Novartis migraine drug not cost effective - U.K. price watchdog

ZURICH, Jan 10 Britain's drug price watchdog on Thursday rejected Novartis's migraine drug Aimovig for now, concluding in a draft decision that the medicine was not a cost-effective use of National Health Service resources.

UPDATE 7-Bristol-Myers to buy Celgene for $74 bln in largest biopharma deal

Jan 3 Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever.

Drug companies greet 2019 with U.S. price hikes

NEW YORK, Jan 2 Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world's top-selling medicine, Humira, although the pace of price hikes was slower than last year.

PRESS DIGEST -Wall Street Journal - Jan 2

Jan 2 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

Photo

Exclusive: Big Pharma returning to U.S. price hikes in January after pause

NEW YORK/SAN FRANCISCO Novartis AG and Bayer AG are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry under pressure from the Trump administration, according to documents seen by Reuters.

Photo

Exclusive: Big Pharma returning to U.S. price hikes in January after pause

NEW YORK/SAN FRANCISCO Novartis AG and Bayer AG are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry under pressure from the Trump administration, according to documents seen by Reuters.

Photo

Allergan stops sale of textured breast implants in Europe, shares sink

NEW YORK Drugmaker Allergan Plc said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered a recall of the implants, which have been linked to a rare form of cancer.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.48%
Rohstoffe -0.16%
Industrie -0.09%
Konjunktur abhängige Waren & Dienstleistungen +0.06%
Konjunktur unabhängige Waren & Dienstleistungen -0.18%
Finanzindustrie -0.05%
Pharma -0.07%
Technologie -0.10%
Telekommunikation +0.01%